$A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy podcast$

Management of Adverse Effects Associated With Novel Therapies

6/9/2022

A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy

0:00

13:25

Management of relapsed/refractory LBCLs remains a substantial and persistent clinical challenge, including optimal treatment sequencing, therapy evaluation and patient selection, and toxicity management.

More episodes from "A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy"

$A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy podcast$
Principles of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma: Patient Selection Strategies
6/9/2022
8:02
Large B-cell lymphomas (LBCLs) are one of the most common subtypes of non-Hodgkin lymphomas and while 1st-line standard of care has remained unchanged, the treatment paradigm has undergone a shift in recent years due to the development of novel therapeutic agents. These novel therapies include monoclonal antibody (mAb) therapies, mAb-conjugates, and chimeric antigen receptor (CAR)-T cell therapies.
$A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy podcast$
Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies
6/9/2022
36:58
Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies
$A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy podcast$
Don't miss an episode of “A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy” and subscribe to it in the GetPodcast app.
$A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy podcast$
Disease Burden and Overview of Large B-Cell Lymphomas
6/9/2022
4:04
B-cell lymphomas consist of a heterogenous group of lymphoproliferative neoplasms originating from B-lymphocytes.  
$A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy podcast$
Management of Adverse Effects Associated With Novel Therapies
6/9/2022
13:25
Management of relapsed/refractory LBCLs remains a substantial and persistent clinical challenge, including optimal treatment sequencing, therapy evaluation and patient selection, and toxicity management.

Get the whole world of podcasts with the free GetPodcast app.

Subscribe to your favorite podcasts, listen to episodes offline and get thrilling recommendations.

Management of Adverse Effects Associated With Novel Therapies

A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy

More episodes from "A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy"

Principles of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma: Patient Selection Strategies

Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies

Disease Burden and Overview of Large B-Cell Lymphomas

Management of Adverse Effects Associated With Novel Therapies